Cardiovascular Diseases

Merck Reports Pivotal PCSK9 Pill Data in Race to Beat AstraZeneca to Market

1 day ago talkbio0Tagged Approved, AstraZeneca, Autoimmune hemolytic anemia, Cardiovascular Diseases, CORALreef trial, enlicitide, LDL-C, Merck, oral cholesterol pill, PCSK9 inhibitor, United States Food and Drug Administration

Merck; PCSK9 inhibitor; enlicitide; oral cholesterol pill; AstraZeneca; CORALreef trial; LDL-C reduction; AHA 2025; FDA approval; cardiovascular disease

Amgen Builds Case for Repatha to Prevent Heart Disease With Landmark Late-Stage Data

1 month ago talkbio0Tagged amgen, Approved, Cardiovascular Diseases, Cardiovascular event, Cerebrovascular accident, LDL-C, Myocardial Infarction, PCSK9 inhibitor, Primary Prevention, Repatha, United States Food and Drug Administration, VESALIUS-CV trial

Amgen; Repatha; VESALIUS-CV trial; primary prevention; cardiovascular disease; PCSK9 inhibitor; LDL-C; FDA approval; major adverse cardiovascular events; heart attack; stroke

Novartis Acquires Tourmaline Bio for $1.4B to Bolster Cardiovascular Pipeline with Promising Phase 2 Drug

2 months ago talkbio0Tagged Acquisition, Anti-Inflammatory Agents, Antibodies, C-reactive protein, Cardiovascular Diseases, Chronic Kidney Diseases, interleukin-6, Novartis, pacibekitug, Phase 2 trial, Tourmaline Bio

Novartis; Tourmaline Bio; acquisition; $1.4 billion; pacibekitug; cardiovascular disease; anti-inflammatory; IL-6 antibody; ASCVD; phase 2 trial; C-reactive protein; chronic kidney disease

Novartis and ProFound Therapeutics Forge $750M-Per-Target Cardiovascular Pact

5 months ago talkbio0Tagged biobucks, biotech partnership, Cardiovascular Diseases, Drug Discovery, Flagship, Novartis, pharmaceutical milestones, ProFound Therapeutics, Proteomics

Novartis; ProFound Therapeutics; cardiovascular disease; biotech partnership; drug discovery; proteomics; biobucks; flagship pioneering; pharmaceutical milestones

Eli Lilly Pays $1B Upfront to Acquire Verve Therapeutics, Expanding Cardiovascular Gene Editing Portfolio

5 months ago talkbio0Tagged Acquisition, Cardiovascular Diseases, eli lilly, Gene Modification, Heart Diseases, PCSK9 protein, human, VERVE-102

Eli Lilly; Verve Therapeutics; gene editing; cardiovascular disease; acquisition; PCSK9; VERVE-102; biotech; heart disease

CRISPR Therapeutics Partners with Sirius for siRNA Therapies, Expanding Beyond Gene Editing

6 months ago talkbio0Tagged Anticoagulants, biotech partnerships, Cardiovascular Diseases, Clustered Regularly Interspaced Short Palindromic Repeats, Factor XI, Gene Modification, RNA, Small Interfering, Sirius, SRSD107, thrombotic disease

CRISPR Therapeutics; Sirius Therapeutics; siRNA; gene editing; SRSD107; cardiovascular diseases; thrombotic disease; biotech partnerships; Factor XI; anticoagulant therapies